JMP keeps Oscient at strong buy

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a strong buy. The Food and Drug Administration voted 11 to 2 against approval Oscient's supplemental New Drug Application to expand the Factive label to include acute bacterial sinusitis due to lack therapeutic benefit evidence. Growing sales of Factive and Antara will drive appreciation in Oscient shares, according to the analyst. Shares of the Waltham, Mass., biopharmaceutical company were down 13 cents, or 11.4%, at $1.01. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.